Naibec Receives Approval for Phase 1 Clinical Trial Plan of Pulmonary Fibrosis Treatment in Australia
[Asia Economy Reporter Lee Jung-yoon] Nivek announced on the 22nd that the Phase 1 clinical trial plan for its peptide-based pulmonary fibrosis treatment (NIPEP-PF, clinical trial code NP-201) in Australia has been approved.
Hot Picks Today
!["Despite Complaints About Sweat, She Straps On a 15kg Bag and Pushes Through the Deadly Heatwave [Sociology of Heatwaves] ①"](https://cwcontent.asiae.co.kr/asiaresize/93/2026081215431278523_1786516992.gif)
"Despite Complaints About Sweat, She Straps On a 15kg Bag and Pushes Through the Deadly Heatwave [Sociology of Heatwaves] ①"
- "We’ll Refund or Resume Trips in Two Years"...Youth Travel Agency Suddenly Halts Operations, Consumers Panic
- "Warnings Are Over"... 100,000 Won Fines for Drinking and Smoking at Cheonggyecheon Amid Rising Disorder
- Chairperson Jungin Cha: "No Need for Private Institutes if Written and Essay Exams Are Introduced... Extensive Reading Is Enough"
- "Controversy Over Female YouTuber Who Filmed in Mixed-Gender Bath Despite Knowing Filming Was Prohibited"
The company stated, "After completing Phase 1 in Australia, depending on the evaluation results of pharmacokinetic characteristics, safety, tolerability, and immunogenicity observed during this clinical process, we plan to proceed to the next phase of patient-targeted clinical trials."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
